Get the Stockscreener App
3.26
10.14%
0.30
After Hours:
3.26
Prokidney Corp stock is traded at $3.26, with a volume of 7.78M.
It is up +10.14% in the last 24 hours and up +50.93% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$2.96
Open:
$2.84
24h Volume:
7.78M
Relative Volume:
0.60
Market Cap:
$440.08M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-5.7193
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
+25.38%
1M Performance:
+50.93%
6M Performance:
+538.09%
1Y Performance:
+88.44%
1-Day Range:
$2.77
$3.41
1-Week Range:
$2.62
$3.41
52-Week Range:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
3.26 | 399.58M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
ProKidney (NASDAQ:PROK) Shares Gap DownWhat's Next? - MarketBeat
Will ASN Spotlight On REGEN-007 Propel ProKidney Toward Accelerated Approval? - RTTNews
Using AI based signals to follow ProKidney Corp.Quarterly Portfolio Report & Advanced Swing Trade Entry Plans - newser.com
What institutional flow reveals about ProKidney Corp.Layoff News & Smart Allocation Stock Reports - newser.com
Smart tools for monitoring ProKidney Corp.’s price actionGap Up & Community Consensus Trade Alerts - newser.com
ProKidney Corp (PROK) Touts Reparencel Therapy for Growth - MSN
Will ProKidney Corp. see short term momentumJuly 2025 Trade Ideas & Safe Entry Point Alerts - newser.com
Is it time to cut losses on ProKidney Corp.2025 Institutional Moves & Consistent Profit Trade Alerts - newser.com
Why ProKidney Corp. stock appeals to dividend seekers2025 Top Gainers & Capital Efficient Trade Techniques - newser.com
ProKidney (NASDAQ:PROK) Trading 8.1% HigherShould You Buy? - MarketBeat
What drives ProKidney Corp stock priceTop Performing Stocks & Create Your Free Watchlist Instantly - earlytimes.in
Is ProKidney Corp a good long term investmentRisk Management Strategies & Low Cost Market Strategies - earlytimes.in
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Layoff Watch: Is TBBB stock a top performer YTDGDP Growth & Weekly High Momentum Picks - khodrobank.com
Earnings Beat: Is ProKidney Corp impacted by rising ratesWeekly Gains Report & Stepwise Trade Execution Plans - khodrobank.com
Whale Trades: What are ProKidney Corp.’s recent SEC filings showingGlobal Markets & Verified Entry Point Detection - خودرو بانک
ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy - Seeking Alpha
ETF Watch: Why is ProKidney Corp stock going downJuly 2025 Review & Community Driven Trade Alerts - خودرو بانک
Risk Recap: Is FLNT’s ROIC above industry averageMarket Activity Summary & Free Expert Verified Stock Movement Alerts - khodrobank.com
Aug Movers: Will ProKidney Corp outperform tech stocks2025 Dividend Review & Fast Gain Stock Trading Tips - خودرو بانک
Market Overview: Is ProKidney Corp stock a top performer YTDTrade Ideas & Expert Approved Momentum Ideas - خودرو بانک
Earnings Recap: Will ProKidney Corp benefit from government policy2025 Geopolitical Influence & Technical Pattern Recognition Alerts - khodrobank.com
Pharma News: Can ProKidney Corp continue delivering strong returns2025 Fundamental Recap & Fast Entry High Yield Stock Tips - khodrobank.com
Risk Report: Does ProKidney Corp meet Warren Buffetts criteriaAnalyst Downgrade & Free Verified High Yield Trade Plans - khodrobank.com
Market Rankings: Why is ProKidney Corp. stock going upPortfolio Value Report & Free Verified High Yield Trade Plans - خودرو بانک
ProKidney (NASDAQ:PROK) Shares Down 6.9%Should You Sell? - MarketBeat
Growth Value: Is Intelligent Bio Solutions Inc part of any major index2025 Fundamental Recap & Accurate Technical Buy Alerts - خودرو بانک
Meme Stocks: Is SAP SE ADRhedged forming a breakout patternTreasury Yields & Free Long-Term Investment Growth Plans - خودرو بانک
Block Trades: Is ProKidney Corp stock undervalued right nowJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Pullback Watch: Can ProKidney Corp weather a recessionJuly 2025 Rallies & Risk Controlled Stock Alerts - خودرو بانک
ProKidney (NASDAQ:PROK) Stock Price Up 21.1%Still a Buy? - MarketBeat
Block Trades: Will ProKidney Corp benefit from government policyJuly 2025 Outlook & Capital Efficiency Focused Strategies - خودرو بانک
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):